ARES Ares Management

Q1 2025 10-Q

Filed: May 6, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Ares Management (ARES) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 6, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New trade policy risks triggered by recent substantial tariffs and restrictive trade policies increasing costs and supply chain disruptions
• Updated legal risk: OFAC No Action letter July 2023 closing prior Iran sanctions investigation involving Platinum Performance acquisition

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.2B

Net Income

$631M

Net Margin

28.4%

Source: XBRL data from Ares Management Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Ares Management Quarterly Reports

Q3 2025 10-Q

Get deeper insights on Ares Management

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.